NCT06567860View on ClinicalTrials.gov

Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

February 6, 2025

Study Completion Date

February 6, 2025

Conditions
Influenza A
Interventions
BIOLOGICAL

Influenza Fluzone vaccine

Fluzone vaccine administered in both May-June and in September-October for each participant.

Trial Locations (1)

92037

La Jolla Institute for Immunology, La Jolla

All Listed Sponsors
lead

La Jolla Institute for Immunology

OTHER

NCT06567860 - Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations | Biotech Hunter | Biotech Hunter